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Abstract
Background: Proteomic-based discovery of biomarkers for disease has recently come under scrutiny for a variety
of issues; one prominent issue is the lack of orthogonal validation for biomarkers following discovery. Validation by
ELISA or Western blot requires the use of antibodies, which for many potential biomarkers are under-characterized
and may lead to misleading or inconclusive results. Gelsolin is one such biomarker candidate in HIV-associated
neurocognitive disorders.
Methods: Samples from human (plasma and CSF), monkey (plasma), monocyte-derived macrophage
(supernatants), and commercial gelsolin (recombinant and purified) were quantitated using Western blot assay and
a variety of anti-gelsolin antibodies. Plasma and CSF was used for immunoaffinity purification of gelsolin which was
identified in eight bands by tandem mass spectrometry.
Results: Immunoreactivity of gelsolin within samples and between antibodies varied greatly. In several instances,
multiple bands were identified (corresponding to different gelsolin forms) by one antibody, but not identified by
another. Moreover, in some instances immunoreactivity depended on the source of gelsolin, e.g. plasma or CSF.
Additionally, some smaller forms of gelsolin were identified by mass spectrometry but not by any antibody.
Recombinant gelsolin was used as reference sample.
Conclusions: Orthogonal validation using specific monoclonal or polyclonal antibodies may reject biomarker
candidates from further studies based on misleading or even false quantitation of those proteins, which circulate in
various forms in body fluids.
Background
The development of global proteomic profiling in the mid-
1990 s raised the expectations for quick discovery of new
biomarkers [1]. More importantly, it was expected that
profiling of body fluids using high throughput, sensitive
and specific methods would result in bringing new and
approved diagnostic and therapeutic biomarkers from
bench to bedside in a fast track manner [2]. However, soon
after the first large profiling experiments were performed,
researchers observed several major problems: (i)v e r yh i g h
dynamic range of the expression of proteins in the body
fluids can reach 10
12 orders of magnitude, thereby exclud-
ing the possibility to quantitate both low and high abun-
dance proteins without additional sample fractionation(s)
[3]; (ii) range of concentration for any given protein varies
from individual to individual in general population as well
as in cohorts of patients; (iii) standard operating
procedures - including sample preparation, mass spectro-
meters used, and bioinformatic database searching - varied
between proteomic labs, resulting in variability and only
partial overlap of results [4]; and (iv) orthogonal validation
of biomarkers in body fluids is essential following discovery
phase, however these methods often fail to confirm initial
results [5].
Of all the issues listed above, several are beyond our
control and others require more technological develop-
ment; validation of quantitative proteomics data is one
such issue requiring advancement [6,7]. Examples of
orthogonal validation techniques for MS-based proteomics
include Enzyme Linked ImmunoSorbent Assay (ELISA)
[8-10] and Western blot [11,12]. In comparison, examples
of parallel validation techniques include Stable Isotope
Standards and Capture by Anti-Peptide Antibodies (SIS-
CAPA) [13,14] and Multiple Reaction Monitoring (MRM)
[15,16]. Each technique has advantages and drawbacks for
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gonal validation using Western blot or ELISA requires the
use of antibodies; some of which are not well characterized
and when used, may result in misleading or skewed data.
Proteomic studies from our laboratory have shown
that gelsolin is differentially expressed in the plasma and
Cerebrospinal Fluid (CSF) of Human Immunodeficiency
Virus (HIV)-infected individuals with and without
dementia [17-19]. Likewise, gelsolin circulating in the
plasma of monkeys infected with simian immunodefi-
ciency virus (SIV) is also differentially expressed
between pre-infection, acute and chronic infection [19].
We have also found that monocyte derived macrophage
(MDM) activated by HIV infection in vitro produce and
secrete gelsolin (Ciborowski, P.; Kraft-Terry, S. both
unpublished). Taking this together, we postulated that if
gelsolin is validated, it may become a candidate as a
diagnostic biomarker and be justified to move to experi-
ments using larger cohorts of patients. However, valida-
tion of the differential expression of gelsolin in body
fluids occurred to be a challenging task, as quantitative
Western blot did not confirm differential expression
unambiguously. As further studies indicated this was
caused by two major reasons. First, high variability in
the immunoreactivity of commercially available antibo-
dies and the variability in recognition of gelsolin origi-
nating from CSF or plasma resulted in ambiguity.
Second, immunoaffinity purification of gelsolin followed
by MS/MS revealed that although the gelsolin circulat-
ing in the plasma and CSF was the secreted form of gel-
solin (plasma gelsolin; pGSN), several other forms in
addition to the full-length molecule (86kDa) were also
in circulation ranging in molecular weight from 10 kDa
to 188 kDa [20]. Based on these prior studies and obser-
vations, this study focused on problems with validation
of gelsolin using antibody based orthogonal assays.
Materials and methods
Samples and Sample Processing
Four sets of human and non-human primate samples were
used throughout this project: two sets of human plasma,
one set of human CSF, and one set of non-human primate
plasma. Human plasma and CSF samples were previously
obtained from the National NeuroAIDS Tissue Consor-
tium (NNTC, http://www.nntc.org) under request #R101.
The samples were classified based only on neurocognitive
status (non-demented [ND], sub-symptomatic, or HIV-
associated dementia [HAD]); no other criteria (age, race,
gender, T-cell count, viral load, etc.) were applied for sam-
ple selection. Two additional sample sets were obtained:
human plasma from the California NeuroAIDS Tissue
Network (CNTN) at the University of California San
Diego, CA (from Drs. I. Grant, R. Ellis, S. Letendre) and
Rhesus macaques plasma samples were obtained from
Dr. Robert M Donahoe, University of Utah, UT [21]. The
UNMC Institutional Review Board approved the use of
the human clinical samples (#196-05-EX).
Prior to any type of sample processing, proteases and
virus were neutralized using a solution of 10 μL-1 0 %
Triton X-100 and 50 μL - 20X cocktail of protease inhi-
bitors (Sigma-Aldrich; St. Louis, MO) per mL of sample
as described previously in Wiederin et al. [19].
Each CSF sample was split into separate parts: one
was used for immunodepletion and another for immu-
noaffinity purification. Immunodepletion was performed
as described in Rozek et al. [18] using the Multiple Affi-
nity Removal Spin Cartridges Hu-6 (Agilent; Santa
Clara, CA). Plasma samples from CNTN, San Diego
were immunodepleted as described in Pottiez et al. [20]
using the Seppro® IgY 14 LC10 Column (Sigma-Aldrich).
Rhesus macaques plasma samples were immunodepleted
as described in Wiederin et al. [19] using the Proteome-
Lab IgY-12 High Capacity Proteome Partitioning Kit
(Beckman Coulter; Fullerton, CA). Following immuno-
depletion, all samples were stored at -80°C.
Non-immunodepleted plasma and CSF samples from
NNTC were pooled based on source and neurocognitive
status immediately before immunoaffinity purification of
gelsolin. A 1 mL capacity HiTrap NHS-activated HP
affinity column (GE Life Sciences; Pittsburg, PA) was
used for immunoaffinity purification and was performed
as described in Pottiez et al. [20]. Protein quantity for
each fraction was analyzed using a NanoDrop 2000
(ThermoScientific, Inc., Waltham, MA) and fractions
containing protein were pooled, dialyzed in MilliQ
water and stored at -80°C.
In addition to plasma and CSF samples, human mono-
cytes were isolated and cultured for this project. Mono-
cytes were isolated by leukophoresis from donors whom
were HIV-1, -2, and hepatitis seronegative as described
in Gendelman et al. [22]. These monocytes were cul-
tured and differentiated as described in Ciborowski
et al. [23] and infection with HIV-1ADA (multiplicity of
infection: 0.1) occurred 7 days post-plating. Cell super-
natants were collected from both HIV-infected and non-
infected control cells at day 3 post-infection.
Commercial Gelsolin and Anti-Human Gelsolin (hGSN)
Antibodies
Human recombinant plasma gelsolin protein was
obtained from Cytoskeleton, Inc. (Denver, CO). Human
plasma gelsolin protein was obtained from Sigma-
Aldrich.
Antibodies used throughout this study included mouse
anti-human gelsolin (hGSN) monoclonal antibody
( m A b )( B DB i o s c i e n c e s ;S a nJ o s e ,C A ) ,g o a ta n t i - h G S N
C-20 polyclonal antibody (pAb) (Santa Cruz Biotechnol-
ogy, Inc.; Santa Cruz, CA),a n dr a b b i ta n t i - h G S Np A b
Haverland et al. Journal of Translational Medicine 2010, 8:137
http://www.translational-medicine.com/content/8/1/137
Page 2 of 10(Abcam; Cambridge, MA). The appropriate horseradish
peroxidase (HRP) conjugated secondary antibodies
(Jackson ImmnoResearch Laboratories, Inc; West Grove,
PA) were used for Western blot. A total of 1 mg goat
anti-hGSN pAb antibody (Santa Cruz Biotechnology)
was purified by protein-G affinity chromatography
(Pierce; Rockford, IL) following manufacturer’s protocol
and used for immunoaffinity purification of samples.
One dimensional gel electrophoresis (1DE) and in-gel
tryptic digest
Samples were desiccated using a SpeedVac (Thermo-
Scientific) and resolubilized in 20 μL NuPAGE (Invitro-
gen; Carlsbad, CA) sample buffer with reducing agent
prior to heating and gel loading. 1DE was performed
using NuPAGE® Novex® precast 4-12% Bis-Tris Gels
(Invitrogen) under reducing conditions. The gel was run
for 90 minutes at 100 V. Human immunoaffinity puri-
fied plasma and CSF derived gelsolin gels were fixed
and stained with brilliant-blue G-colloidal concentrate
(Sigma-Aldrich). Remaining samples were used for
Western blot.
Bands from plasma immunoaffinity purified gelsolin
samples were excised using a razor blade, destained, and
digested in-gel using modified trypsin. Destaining con-
sisted of two 30-minute washes using first 200 μLo f2 0
mM NH4 HCO3/50% acetonitrile (ACN), then 200 μL
of 100% ACN. After destaining, the gel slices were
desiccated and treated with 0.1 μg/μLs e q u e n c i n gg r a d e
modified trypsin (Promega; Madison, WI) overnight at
37°C. Next, the peptides were extracted using 60% ACN,
0.1% TFA solution, desiccated and resuspended in 0.1%
TFA. Reverse-phase C18 Zip-Tips® (Millipore; Billerica,
MA) were used to purify extracted peptides following
manufacturer’s protocol.
Identification by LC/ESI-MS/MS
Mass spectrometric analysis was carried out using an
LC/ESI-MS/MS system in a nanospray configuration
using a microcapillary reverse phase RP-C18 column
(New Objectives; Woburn, MA). An LCQ-Deca XP Plus
ion trap mass spectrometer (ThermoScientific, Inc.) was
used to perform tandem mass spectrometry. Spectra
were searched and proteins were identified following
procedures stated in Pottiez et al. [20].
Western blot
Following electrophoresis, proteins were transferred to a
polyvinylidene fluoride (PVDF) membrane (Bio-Rad;
Hercules, CA) for immunodetection as previously
described in Ciborowski et al. [24]. Manufacturer’s
recommendations were followed for each antibodies
used in the detection of gelsolin in samples; each
primary (anti-hGSN) antibody was used at a 1:1000
dilution in phosphate buffered saline with 0.02% Tween-
20 (PBST) and 10% (w/v) skim milk; each secondary
antibody was used at a 1:20,000 dilution.
ExPASy Compute pI/Mw tool
Based on the sequences identified using LC/ESI-MS/MS,
the theoretical molecular weight was calculated using
the ExPASy Compute pI/Mw tool http://www.Expasy.
org. For each band, the peptides from the most N-
terminal and C-terminal regions were selected as the
form endpoints. Using the FASTA sequence for secreted
pGSN, all amino acids between those N-terminal and
C-terminal amino acids were identified and this
shortened sequence was used to generate a theoretical
molecular weight.
Results
Previously published MS-based proteomic studies have
shown that plasma gelsolin (pGSN) is differentially
expressed in HIV infected humans, SIV infected mon-
keys and in vitro HIV infected MDM [18-20,23]. Prior
to conducting further studies using larger cohorts of
samples from patients, we attempted to validate its
expression using a smaller number of samples. Our vali-
dation effort using quantitative Western blot analysis
gave ambiguous results and indicated that differences in
validation strongly depend on which antibody was used.
Therefore, the initial goal of our study was to select an
anti-gelsolin antibody that when used for quantitative
Western blot analysis would most closely reflect the
results of proteomic profiling.
Specificity of anti-gelsolin antibodies
Subsequent experiments brought to light new informa-
tion concerning our previous results of Western blot vali-
dations [25] in which we observed a single band
corresponding to the full-length gelsolin molecule. Con-
current experiments of immunoaffinity purification from
the same samples showed multiple forms of gelsolin.
This discrepancy prompted us to further explore the spe-
cificity of anti-hGSN antibodies to explain if Western
blot validation of proteomic profiling might be biased
and do not reflect real levels of intact and processed
forms of gelsolin. From more than 20 commercially avail-
able anti-hGSN antibodies, we selected three: mouse
monoclonal, goat polyclonal and rabbit polyclonal; all
were raised against an epitope from the C-terminal por-
tion of gelsolin. A sheep polyclonal anti-hGSN antibody
was also tested, but results could not be obtained due to
high background (data not shown). Figure 1A is a sche-
matic diagram of the gelsolin molecule along with the
location of the epitope corresponding to each antibody.
Figure 1B summarizes the specificity of those three anti-
hGSN antibodies used for Western blot assay against the
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Figure 1 Immunorecognition of hGSN by three antibodies in Western blot assay. (A) The location of epitope specific to the mouse, goat and
rabbit anti-hGSN antibodies are provided in reference to the full-length pGSN. Numbers above each epitope correspond to the amino acid sequence
from the full-length (with signal sequence intact) pGSN containing peptides used as antigens. (B) Summary of Western blot analyses revealing that
immunoreactivity of pGSN depends on not only antibodies but also source of antigen. Total protein loaded per source per lane: 25 μgo fh u m a n
plasma from HIV-infected individuals, 10 μg of human CSF from HIV-infected individuals, 20 μg of cell supernate from both HIV-infected and non-
infected cells, 25 μg of monkey plasma from pre- and 10 days post-infection of rhesus macaques with SIV, and 2 μg each of commercially available
gelsolin. Membranes from each source were probed with mouse anti-hGSN, goat anti-hGSN, and rabbit anti-hGSN (all 1:1000) and corresponding HRP-
conjugated secondary antibodies (1:20,000) diluted in PBS supplemented with 10% Tween-20 and 10% (w/v) skim milk.
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that monoclonal antibody raised to a synthetic peptide
(located in the C-terminal end of gelsolin) reacted only
with a single band of approximately 86 kDa, correspond-
ing to the full length and intact gelsolin molecule. This
indicated the conformational dependence of the anti-
body; moreover, it suggested that the conformation of
the entire molecule - not only its C-terminal portion - is
necessary for its immunoreactivity. Furthermore, Wes-
tern blot analysis using either goat or rabbit pAb recog-
nized additional forms of gelsolin with both larger and
smaller molecular weights. It is likely that the smaller
molecular weight forms are truncated forms of the full-
length molecule based on trends observed by LC/ESI-
MS/MS (Table 1). Further analysis using LC/ESI-MS/MS
revealed that the larger molecular weight form (Figure
2A, asterisked band) contains fibronectin, which co-
immunopurified with gelsolin; this comes as no surprise
as it is well known that fibronectin binds gelsolin [26].
It was most unexpected that goat and rabbit pAb
showed such great differences in immunoreactivity
within samples. For example, goat pAb reacted weakly
with only one form of gelsolin in the CSF whereas rabbit
pAb recognized strongly two forms of gelsolin in that
same sample. None of these antibodies recognized a form
of gelsolin in any sample with a molecular weight lower
than 45 kDa with the exception of goat pAb against com-
mercially available human pGSN (Sigma Aldrich), which
was able to recognize an additional band with a molecu-
lar weight of less than 38 kDa. In addition to the lower
molecular weight forms, there were several samples in
which higher molecular weight forms were detected; goat
anti-hGSN pAb was able to detect these higher molecular
weight forms in both human plasma and commercial gel-
solin samples. Protein purification and concentration can
often cause proteins to aggregate, which is a potential
explanation for these higher molecular weight bands.
These higher molecular weight bands warranted further
investigation and using LC/ESI-MS/MS on bands excised
from recombinant gelsolin, we were able to positively
identify only gelsolin.
Immunoaffinity purification of gelsolin
from plasma or CSF
1DE of immunoaffinity purified CSF and plasma derived
gelsolin revealed several bands with a wide range of mole-
cular weights: approximately 17 kDa to >188 kDa (Figure 2
columns A and B). Although the relative concentration for
each band varied between immunoaffinity purified gelsolin
from plasma and CSF, the banding pattern remained con-
sistent suggesting processing of gelsolin in the plasma and
CSF is similar. Western blot analysis of recombinant
plasma gelsolin using mouse anti-hGSN showed a single
band at 86 kDa, which corresponds to the full-length
gelsolin molecule (Figure 2 column D). In comparison,
Western blot of this same sample using goat anti-hGSN
revealed multiple bands at 166 kDa, 86 kDa, 64 kDa, 60
kDa, 54 kDa, and 45 kDa (Figure 2 column C).
Eight bands were selected for tryptic digestion and
identification by LC-ESI-MS/MS from the immunoaffi-
nity purified plasma sample (Figure 2 column A). Gelso-
lin was found in each band; the peptides that were
identified and their exact location in secreted pGSN are
included in Table 1. The approximate molecular weight
for each band as estimated by electrophoretic mobility is
included. Furthermore, a theoretical minimum molecu-
lar weight for each band based on the peptides identified
in that band and calculated using the ExPASy Compute
pI/Mw tool was also included in Table 1. Some peptides
were identified in almost every band, whereas several
were identified in only one or two bands. Based on the
peptides identified, it was determined that the forms
present in immunoaffinity purified samples were mainly
truncated from the N-terminal end.
Due to the immunodetection pattern observed in the
Western blots (Figure 1 and Figure 2: columns C and D),
it was further postulated that the pGSN forms in bands 7
and 8 (Figure 2 column A) were likely either (i) at a con-
centration below the detectable threshold via Western
blot, (ii) truncated at the C-terminal end and thereby
lacking the immunogen required to be recognized by the
antibody, and/or (iii) in an alternative conformation due
to post-translational modifications or from changes
occurring during 1DE and transfer.
Immunoreactivity of gelsolin forms
Figure 3 includes a Western blot using goat anti-hGSN
antibodies against a linear dilution of recombinant gel-
solin. In the most concentrated sample (2 μg) of GSN, a
total of 3 clear and distinguishable bands were detected:
>188, 60 and 54 kDa both representing different forms
of pGSN. Also detected were two bands at 166 kDa and
86 kDa; these bands however were not clear and distin-
guishable, but instead were oversaturated and unquanti-
fiable. A 7-fold dilution (0.016 μg) of GSN resulted in
only one clear, distinguishable and quantifiable band at
86 kDa. It was determined that immunodetection using
goat anti-hGSN is dependent on the concentration of
each form present in the sample.
Based on the banding pattern observed, peptides recog-
nized and their location, molecular weight observed for
each band and the calculated theoretical minimum mole-
cular weight, a schematic for each band was created
(Figure 4).
Disscusion
Biomarker discovery and validation - or even the com-
plete characterization - of the plasma and/or proximal
Haverland et al. Journal of Translational Medicine 2010, 8:137
http://www.translational-medicine.com/content/8/1/137
Page 5 of 10Table 1 LC/ESI-MS/MS identification of immunoaffinity purified forms of gelsolin
Gel band M.W.* Theoretical minimum M.W. ** Peptide sequence Peptide position in pGSN
Band 1 86 kDa 65816.00 kDa EVQGFESATFLGYFK 121 - 135
HVVPNEVVVQR 151 - 161
PALPAGTEDTAKEDAANR 251 - 268
QTQVSVLPEGGETPLFK 347 - 363
DPDQTDGLGLSYLSSHIANVER 371 - 392
AGALNSNDAFVLK 558 - 570
TPSAAYLWVGTGASEAEK 571 - 588
AQPVQVAEGSEPDGFWEALGGK 600 - 621
DSQEEEKTEALTSAK 687 - 701
RYIETDPANR 702 - 711
RTPITVVK 714 - 721
Band 2 83 kDa 50126.19 kDa PALPAGTEDTAK 251 - 262
QTQVSVLPEGGETPLFK 347 - 363
DPDQTDGLGLSYLSSHIANVER.V 371 - 393
AQPVQVAEGSEPDGFWEALGGK.A 600 - 621
DSQEEEKTEALTSAK 687 - 701
YIETDPANR 703 - 711
Band 3 64 kDa 64805.80 kDa R.EVQGFESATFLGYFK.S 120 - 136
K.PALPAGTEDTAK.E 250 - 263
K.QTQVSVLPEGGETPLFK.Q 346 - 364
K.DSQEEEKTEALTSAK.R 686 - 702
R.YIETDPANR.D 702 - 712
-.YIETDPANR.- 703 - 711
Band 4 60 kDa 49194.23 kDa K.PALPAGTEDTAK.E 250 - 263
R.DPDQTDGLGLSYLSSHIANVER.V 370 - 393
K.AGALNSNDAFVLK.T 557 - 571
R.AQPVQVAEGSEPDGFWEALGGK.A 599 - 622
K.DSQEEEKTEALTSAK.R 686 - 702
Band 5 54 kDa 41077.02 kDa K.QTQVSVLPEGGETPLFK.Q 346 - 364
R.DPDQTDGLGLSYLSSHIANVER.V 370 - 393
K.VPVDPATYGQFYGGDSYIILYNYR.H 430 - 455
K.AGALNSNDAFVLK.T 557 - 571
-.TGAQELLR.- 589 - 596
R.AQPVQVAEGSEPDGFWEALGGK.A 599 - 622
K.DSQEEEKTEALTSAK.R 686 - 702
-.RTPITVVK.- 714 - 721
Band 6 45 kDa 36044.42 kDa R.VPFDAATLHTSTAMAAQHGMDDDGTGQK.Q 392 - 421
K.VPVDPATYGQFYGGDSYIILYNYR.H 430 - 455
K.AGALNSNDAFVLK.T 557 - 571
K.TPSAAYLWVGTGASEAEK.T 570 - 589
R.AQPVQVAEGSEPDGFWEALGGK.A 599 - 622
K.DSQEEEKTEALTSAK.R 686 - 702
R.RYIETDPANR.D 701 - 712
R.YIETDPANR.D 702 - 712
R.RTPITVVK.Q 713 - 722
Band 7 27 kDa 30525.25 kDa VPVDPATYGQFYGGDSYIILYNYR 431 - 454
AGALNSNDAFVLK 558 - 570
RYIETDPANR 702 - 711
Band 8 19 kDa 29308.93 kDa VPVDPATYGQFYGGDSYIILYNYR 431 - 454
DSQEEEKTEALTSAK 687 - 701
Included is the band identification (corresponding to extracted bands in Figure 1, column A), molecular weight based on electrophoretic mobility, theoretical minimum
molecular weight as calculated using ExPASy Compute pI/Mw tool, identified peptides, and peptide location in secreted pGSN. The peptide -DSQEEKTEALTSAK- was the most
commonly identified peptide (in 7 of 8 bands). * - Molecular weight (M.W.) is approximate based on electrophoretic mobility in 1DE SDS-PAGE. ** - Theoretical Molecular weight
was approximated using the ExPASy Compute pI/Mw tool and was calculated using the first peptide position through the last peptide position as determined using MS/MS.
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Page 6 of 10fluids (including CSF) has been a daunting task. New
biomarkers have not emerged as expected, despite the
effort put forth experimentally by both small, single
laboratories with limited clinical samples [3,13,27] as
well as large, research organizations like the Human
Plasma Proteome Project (HPPP) [28]. A conundrum
has emerged with respect to validation of biomarkers
following the discovery phase; is a lack of validation due
to the assumptions that have been made about how a
p a r t i c u l a rd i s e a s ep r o g r e s s e so ri si tt h a tt h et o o l sa n d
reagents used are not adequate to the task? Accordingly,
we postulate that a better understanding of the molecu-
lar mechanisms underlying diseases will help us to
understand observed changes at the protein level and
will also result in the validation of already discovered as
well as new biomarker candidates.
For the majority of studies validation is based entirely
or in part on immunoreactivity of specific antibodies. In
t e r m so fE L I S A ,t h i sa p p r o a c hh a sb e e np r o v e na sv e r y
useful and accurate in many instances, e.g. measurement
of bacterial proteins/toxins etc. However, when the
dynamic changes of human proteins are measured or
taken into consideration (including alternative splicing,
post translational modification, regulated processing or
degradation), immunoreactivity based assays become
quite inaccurate. There has been and will continue to be
attempts to improve these assays and thereby promote
the acceptance of scientifically sound biomarkers. For
example, Rifai et al.p r o p o s e dab i o m a r k e r“pipeline”
including discovery, qualification, verification, assay opti-
mization, validation and commercialization to help aid
in the discovery of better protein biomarkers [29].
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bodies - from immunoaffinity purification in the qualifi-
cation and verification stages to immunoassays like
Western blot and ELISA in validation.
Experimental data that we present in this study helps
to understand why in many cases validation based on
immunoreactivity may lead to inconclusive or even mis-
leading results. Moreover, we also conclude that other
methods such as MRM may provide inaccurate results
in the validation of biomarkers. For example, quantita-
tive methods requiring the use of antibodies such as
ELISA and quantitative Western blot will vary depend-
ing on which antibody is used (Figure 1 and Figure 2).
Additionally, it was shown that the concentration of the
biomarker in question might also adversely affect the
results of quantitation using Western blot (Figure 3).
With respect to quantitation, the different immunoaffi-
nity purification methods used in sample preparation
must also be considered. To date, our laboratory has yet
to witness non-specific removal of gelsolin forms, how-
ever it has been realized that using different methods of
immunoaffinity purification may adversely affect the
quantitation of protein. Therefore using different meth-
ods of immunoaffinity purification should not be used
in quantitative studies, but may be included in qualita-
tive based studies. Furthermore, based on the results of
this study, we reaffirmed that the conformation of the
antigen does plays a key role for immunodetection; this
w a ss e e nw i t ht h eW e s t e r nb l o t su s i n gm o u s ea n t i -
hGSN antibody in Figures 1 and 2 being only able to
detect a single gelsolin form. Additionally, goat anti-
hGSN antibody was able to pull down various forms of
gelsolin in human plasma during immunoaffinity purifi-
cation; however it was unable to detect all the forms fol-
lowing 1DE, transfer and Western blot.
Our results reported here and those reported in pre-
vious papers [30-32] have a much broader implication
to which method should be used for validation and
eventually which potential biomarker candidate will be
used or rejected from testing on larger cohorts of clini-
cal samples.
Although ELISA has long been considered both reli-
able and high throughput and it is a technique that uti-
lizes conjugated antibodies to quantify the targeted
proteins, it also has limitations in its ability to differenti-
ate between protein forms. In comparison, the Western
blot - which is able to detect expression changes in the
various forms of any given protein addressing the limita-
tion of ELISA - is not a high-throughput technique and
its reliability is often questioned because of saturation of
chemiluminescent signal measured with X-ray films.
Standardization of Western blot is much more difficult
even if a fluorescently tagged secondary antibody is
used. Protein microarrays, which address the issue of
high-throughput, is also based on antigen-antibody
interaction and must be performed using very well char-
acterized antibodies. If an antibody used for microarrays
recognizes only one or two forms, only a fragment of
information about the differential expression of any pro-
tein will be received, similar to Western blot assay.
Therefore, the 2D-differential in-gel electrophoresis
(DIGE) profiling method - which separates full-length
forms from fragments (resulting from processing or
degradation) - appears to be an attractive alternative
method. In our previous profiling studies using 2D-
DIGE, we were able to show that the best indicator of
changes of complement C3 in CSF, which is processed
by multi-step well-defined mechanism, is a “residual” a-
40 chain [18]. However, lack of good antibody to this
fragment of C3 made orthogonal Western blot valida-
tion impossible at that time.
A novel approach known as Stable Isotope Standards
and Capture by Anti-Peptide Antibodies (SISCAPA) was
developed to allow for the enrichment of targeted pro-
teins in complex samples [33] and thereby could facili-
tate biomarker validation. This method is based on
peptide quantitation in complex mixtures such as the
total tryptic digest of plasma samples. The SISCAPA
method first combines immunoaffinity purified native
peptide using anti-peptide antibodies immobilized on
100-nanoliter column and spiked stable-isotope-labeled
internal standard peptide of the same sequence. Next,
both peptides are measured by ESI-MS/MS and quantity
is calculated based on the ratio of heavy (standard) to
light (native) peptide, much like multiple reaction moni-
toring (MRM, below). Although the SISCAPA method
may lead to increased sensitivity, it is a technology uti-
lizing antibodies and therefore the same concerns with
respect to ELISA and Western blot are applicable.
The MRM approach for validation is based on the
comparison of abundance of selected peptides originat-
ing from a sample and spiked standard [16,34]; usually
the peptides that are well ionized are selected for MRM
quantitation. However, ambiguous results may occur
depending on the peptide(s) chosen. For example, if one
peptide is selected from N-terminal end of gelsolin and
one from C-terminal region for MRM quantitation (or
SISCAPA), the results of quantitative comparisons can
be very different, as shown in Figure 5. More impor-
tantly, each peptide reflects a different situation; the N-
terminal peptide will indicate quantity of full-length
molecule and multimers whereas the C-terminal peptide
will reflect the degree of gelsolin processing and/or
degradation. Such an ambiguous result, if not further
Haverland et al. Journal of Translational Medicine 2010, 8:137
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Page 8 of 10explained, may result in the rejection of a putative bio-
marker from further studies. Additionally, if a third pep-
tide from the mid-region is selected and the quantity is
averaged, the end result may not be different than the
control sample and potential biomarker will also be
rejected from further studies.
Gelsolin is a candidate biomarker for several neuro-
cognitive diseases but before it can be integrated into
the “biomarker pipeline” [29], further steps must be
made to improve the immunoreactivity of anti-gelsolin
antibodies. Without further antibody development, char-
acterization and optimization, candidate biomarkers
such as gelsolin will lack quantitative validation and
thereby be unable to enter clinical assay development.
Conclusions
Validation is one of the critical steps in bringing new
biomarkers from bench to bedside in translational
research. Our data presented here using gelsolin as an
example, highlights a set of specific problems associated
with antibody based validation methods. We also briefly
describe how each of the current widely accepted meth-
ods of validation has inherent weaknesses yet each are
strong enough that if used alone may lead to ambiguous
or even false results. Hence, conclusions based on our
experimental data have a broad application as to how
we should approach validation methodologically and
partially explains lack of real progress in the translation
of biomarkers from bench to bedside.
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